Holding

Unity BiotechnologyUNITY

Senolytic pioneer targeting age-related diseases; ocular program in Phase 2.

weight · 12.00%·sector · Healthcare·exchange · NASDAQ

Price

TradingView Advanced Chart

Snapshot

Quote + description

Technical analysis

Oscillators + moving averages

Fundamentals

Revenue / margins / balance sheet

Company profile

News

Ticker-scoped headlines
Investment research & data tool · not investment advice · not a regulated broker or advisor · past performance does not guarantee future results.